News
Best Treatment for Newly Diagnosed Multiple Myeloma
A recent article published in JAMA Oncology1 questions whether VRd should remain as the standard of care (SOC) in newly diagnosed multiple myeloma. Careful analysis of the ENDURANCE (E1A11) phase III trial2 raises the question whether VRd continues to be the SOC for...
FDA approves isatuximab in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior...
FDA Approves First CAR-T Cell Therapy ide-cel for R/R Myeloma
The U.S. Food and Drug Administration Approved Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel) (ide-cel), On Friday March 26th. Ide-cel is the first anti-BCMA CAR T cell therapy for relapsed or refractory multiple myeloma. The treatment was...
Top Headlines and Journal Articles for the Week of March 22, 2021
Here is a roundup of articles and news stories the MYELOMA360 team found interesting this week. Whole Genome Sequencing Offers New Diagnostic Insights for Multiple Myeloma Precursor Conditions Researchers at Sylvester Comprehensive Cancer Center at the...
Whole Genome Sequencing Offers New Diagnostic Insights for Multiple Myeloma Precursor Conditions
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that whole genome sequencing can help determine which patients with a multiple myeloma precursor condition, called MGUS or smoldering myeloma,...
COVID-19 in a Multiple Myeloma Patient
Multiple myeloma patients are often treated with immunomodulatory drugs, proteasome inhibitors or monoclonal antibodies until disease progression. Chronic therapy in combination with the underlying disease frequently results in severe humoral and cellular...
Featured Content
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Join Our Community
By joining the MYELOMA360 community, you will receive regular updates with news, information, insights and expert opinions.
Of course, you can opt out at any time.